Endocrine Pharmacology — MCQs

Endocrine Pharmacology Indian Medical PG Practice Questions and MCQs

Question 421: All are short-acting and rapid-acting insulins, EXCEPT:

A. Lispro
B. Aspart
C. Glargine (Correct Answer)
D. Glulisine

Explanation: **Explanation:** The question asks to identify the insulin analog that is **not** short or rapid-acting. Insulin preparations are classified based on their onset and duration of action into rapid, short, intermediate, and long-acting categories. **1. Why Glargine is the correct answer:** **Glargine** is a **long-acting (basal) insulin analog**. It is formulated at an acidic pH (4.0), which causes it to microprecipitate upon subcutaneous injection. This results in slow, constant absorption over 24 hours without a pronounced peak. Because it provides a steady "basal" level of insulin, it is used to control blood sugar between meals and overnight, rather than for immediate postprandial glucose spikes. **2. Why the other options are incorrect:** * **Lispro, Aspart, and Glulisine** are all **Rapid-Acting Insulin Analogs**. * They are designed to dissociate rapidly into monomers after injection, leading to a quick onset (5–15 minutes) and a short duration (3–5 hours). * They are used specifically for "prandial" (mealtime) coverage to mimic the physiological insulin bolus. **3. NEET-PG High-Yield Pearls:** * **The "LAG" Mnemonic:** Remember **L**ispro, **A**spart, and **G**lulisine as the **Rapid-acting** analogs (they "don't lag" behind). * **Peakless Insulin:** Glargine and Degludec are considered "peakless," reducing the risk of nocturnal hypoglycemia. * **Longest Acting:** **Degludec** has the longest half-life (>40 hours). * **IV Use:** While Regular (Short-acting) insulin is the standard for IV use in DKA, rapid-acting analogs can also be given IV, but long-acting insulins (Glargine/Detemir) are **never** given intravenously.

Question 422: Which of the following statements regarding Vitamin D3 is false?

A. Chronic administration of large doses can result in hypervitaminosis.
B. It is useful in postmenopausal osteoporosis.
C. Its active metabolite is calcitriol.
D. It is ineffective in the treatment of vitamin D resistant rickets. (Correct Answer)

Explanation: ### Explanation **1. Why Option D is the Correct (False) Statement:** Vitamin D resistant rickets (VDRR), most commonly **X-linked hypophosphatemia**, is characterized by impaired phosphate reabsorption and defective activation of Vitamin D. While standard doses of Vitamin D are ineffective, the condition is treated with **high doses of Vitamin D (or its active metabolites like Calcitriol)** along with oral phosphate supplements. Therefore, saying it is "ineffective" is clinically incorrect; it is a mainstay of treatment, albeit at much higher pharmacological doses. **2. Analysis of Other Options:** * **Option A (True):** Vitamin D is a fat-soluble vitamin stored in the body. Chronic ingestion of large doses (hypervitaminosis D) leads to hypercalcemia, ectopic calcification, and renal stones. [1] * **Option B (True):** Vitamin D3 (Cholecalciferol) enhances calcium absorption from the gut. [1] It is a standard component of therapy for postmenopausal osteoporosis to maintain bone mineral density and reduce fracture risk. * **Option C (True):** Vitamin D3 undergoes hydroxylation in the liver (to 25-OHD3) and then in the kidney (via 1-alpha-hydroxylase) to form **1,25-dihydroxycholecalciferol**, also known as **Calcitriol**, which is the most potent active metabolite. [1] **3. NEET-PG High-Yield Pearls:** * **Active Form:** Calcitriol (1,25-(OH)₂D₃). [1] * **Storage Form:** Calcidiol (25-OHD₃) — this is what we measure to check for Vitamin D deficiency. [1] * **Drug of Choice in Renal Failure:** Calcitriol or Alfacalcidol (because the kidney cannot perform 1-alpha-hydroxylation). [1] * **Vitamin D Toxicity Treatment:** Immediate withdrawal of the drug, low calcium diet, plenty of fluids, and **Corticosteroids** (which antagonize Vitamin D action).

Question 423: Which of the following is the drug of choice for the treatment of inappropriate antidiuretic hormone secretion?

A. Frusemide
B. Hydrochlorothiazide
C. Spironolactone
D. Demeclocycline (Correct Answer)

Explanation: ### Explanation **Correct Option: D. Demeclocycline** **Mechanism and Rationale:** Syndrome of Inappropriate Antidiuretic Hormone (SIADH) is characterized by excessive ADH secretion, leading to water retention and dilutional hyponatremia. **Demeclocycline**, a tetracycline derivative, is the drug of choice for chronic SIADH because it acts as a **selective ADH antagonist** at the renal collecting ducts. It induces a state of reversible **nephrogenic diabetes insipidus**, thereby promoting water excretion (aquaresis) and correcting hyponatremia. **Analysis of Incorrect Options:** * **A. Frusemide (Furosemide):** While loop diuretics can be used in acute, severe SIADH (along with hypertonic saline) to limit water reabsorption, they are not the primary long-term treatment. They primarily target the Loop of Henle, not the ADH receptors. * **B. Hydrochlorothiazide:** Thiazides are actually used to treat *Diabetes Insipidus* (by causing mild hypovolemia and increasing proximal salt/water reabsorption). In SIADH, they would worsen hyponatremia by increasing sodium excretion. * **C. Spironolactone:** This is an aldosterone antagonist used for edema in heart failure or cirrhosis. It has no effect on ADH or the water-handling pathology of SIADH. **NEET-PG High-Yield Pearls:** * **Vaptans:** Tolvaptan (oral) and Conivaptan (IV) are newer **Vasopressin receptor antagonists** (V2 blockers) and are increasingly preferred over Demeclocycline in modern practice due to a better safety profile. * **Side Effect:** A major side effect of Demeclocycline is **nephrotoxicity** and photosensitivity. * **Fluid Restriction:** The first-line non-pharmacological management for SIADH is always **fluid restriction**. * **Caution:** Rapid correction of hyponatremia must be avoided to prevent **Osmotic Demyelination Syndrome** (Central Pontine Myelinolysis).

Question 424: Octreotide is indicated in all of the following conditions except?

A. Bleeding esophageal varices
B. Secretory diarrhea
C. Infective diarrhea (Correct Answer)
D. Acromegaly

Explanation: **Explanation:** **Octreotide** is a synthetic long-acting analogue of **Somatostatin**. It acts as a potent inhibitor of various physiological processes, including the secretion of growth hormone, insulin, glucagon, and gastrointestinal hormones. **Why Option C is the Correct Answer:** Octreotide is **not indicated** in infective diarrhea. In cases of infection (e.g., Cholera, Shigella), the body’s primary mechanism to clear the pathogen is through intestinal motility and secretion. Octreotide inhibits intestinal motility and secretion, which can lead to the retention of toxins and pathogens, potentially worsening the clinical condition. Management of infective diarrhea focuses on rehydration and appropriate antimicrobial therapy. **Analysis of Incorrect Options:** * **A. Bleeding Esophageal Varices:** Octreotide causes **splanchnic vasoconstriction** (by inhibiting vasodilatory hormones like glucagon). This reduces portal venous pressure and helps control variceal bleeding. * **B. Secretory Diarrhea:** It is highly effective in treating secretory diarrhea associated with **VIPomas, Carcinoid syndrome, and HIV/AIDS**, as it inhibits the secretion of water and electrolytes into the gut lumen. * **D. Acromegaly:** As a somatostatin analogue, it directly inhibits the release of **Growth Hormone (GH)** from the anterior pituitary, making it a first-line medical therapy for acromegaly. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Agonist at somatostatin receptors (SSTR-2 and SSTR-5). * **Other Indications:** Glucagonoma, Gastrinoma (Zollinger-Ellison Syndrome), and dumping syndrome. * **Side Effects:** Biliary sludge and **gallstones** (due to inhibition of cholecystokinin and gallbladder contraction), steatorrhea, and nausea. * **Diagnostic Use:** Radiolabeled octreotide (OctreoScan) is used for localizing neuroendocrine tumors.

Question 425: Which of the following anti-diabetic drugs can be used safely in renal failure?

A. Metformin
B. Sitagliptin
C. Linagliptin (Correct Answer)
D. Canagliflozin

Explanation: **Explanation:** The correct answer is **Linagliptin**. The primary medical concept here is the **route of elimination**. Most oral hypoglycemic agents (OHAs) are excreted renally, requiring dose adjustments or discontinuation as the Glomerular Filtration Rate (GFR) declines to prevent drug accumulation and toxicity. **Why Linagliptin is correct:** Linagliptin is a DPP-4 inhibitor characterized by a unique **non-renal (primarily biliary/fecal) excretion** pathway. Approximately 90% of the drug is excreted unchanged in the feces. Therefore, it is the only DPP-4 inhibitor that requires **no dose adjustment** across all stages of renal impairment, including end-stage renal disease (ESRD). **Why the other options are incorrect:** * **Metformin:** It is excreted unchanged by the kidneys. It is contraindicated when eGFR is <30 mL/min due to the high risk of **lactic acidosis**. * **Sitagliptin:** While also a DPP-4 inhibitor, it is primarily excreted renally. It requires significant dose reductions as renal function declines. * **Canagliflozin:** As an SGLT-2 inhibitor, its efficacy depends on filtered glucose load. It is generally not initiated if eGFR is <30 mL/min and is less effective as renal function worsens. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic:** Remember **"L"** in **L**inagliptin stands for **L**iver (Biliary) excretion. * **Safe in Renal Failure:** Other OHAs safe in renal failure include **Pioglitazone** (metabolized by liver) and **Repaglinide** (primarily fecal excretion). * **Insulin:** In advanced renal failure, insulin requirements actually *decrease* because the kidney is a site for insulin degradation. * **DPP-4 Inhibitors:** All end in the suffix **"-gliptin."** Except for Linagliptin, all require renal dose adjustment.

Question 426: Which of the following conditions is NOT treated with Bromocriptine?

A. Parkinsonism
B. Prolactinoma
C. Endogenous depression (Correct Answer)
D. Infertility

Explanation: **Explanation:** **Bromocriptine** is a potent **Dopamine (D2) receptor agonist** and a derivative of ergot alkaloids. Its clinical utility is derived from its ability to mimic dopamine in various pathways of the brain. 1. **Why Endogenous Depression is the Correct Answer:** Bromocriptine has no established role in treating endogenous depression. Depression is primarily associated with deficiencies in serotonin and norepinephrine (Monoamine hypothesis). While dopamine plays a role in the reward system, D2 agonists like Bromocriptine are not standard antidepressants and can occasionally cause psychiatric side effects like hallucinations or mood disturbances. 2. **Analysis of Incorrect Options:** * **Parkinsonism:** Bromocriptine acts on D2 receptors in the striatum, helping to restore the dopamine-acetylcholine balance. It is used as an adjunct to Levodopa or as monotherapy in early Parkinson's. * **Prolactinoma:** Dopamine is the physiological "Prolactin Inhibiting Factor." Bromocriptine stimulates D2 receptors on pituitary lactotrophs, effectively shrinking prolactin-secreting tumors and lowering serum prolactin levels. * **Infertility:** Hyperprolactinemia causes infertility by inhibiting GnRH secretion (leading to anovulation). By suppressing prolactin, Bromocriptine restores the normal ovulatory cycle and treats infertility in hyperprolactinemic patients. **High-Yield Clinical Pearls for NEET-PG:** * **DOC:** Bromocriptine was traditionally the drug of choice for prolactinomas, but **Cabergoline** is now preferred due to its higher efficacy, longer half-life (twice weekly dosing), and better side-effect profile. * **Other Uses:** It is also used in **Acromegaly** (paradoxically decreases GH) and **Type 2 Diabetes Mellitus** (Quick-release formulation). * **Side Effects:** Nausea, vomiting (due to CTZ stimulation), and postural hypotension are common. Long-term use of ergot derivatives is associated with **retroperitoneal/cardiac valvular fibrosis**.

Question 427: Which of the following agents has the lowest risk of causing nausea and vomiting?

A. Semaglutide
B. Lixisenatide
C. Albiglutide (Correct Answer)
D. Liraglutide

Explanation: **Explanation:** The question focuses on the side effect profile of **GLP-1 Receptor Agonists (GLP-1 RAs)**. Nausea and vomiting are the most common adverse effects of this class, occurring due to delayed gastric emptying and direct activation of the area postrema in the CNS. **Why Albiglutide is Correct:** The incidence of gastrointestinal (GI) side effects is largely determined by the **pharmacokinetics** and **molecular size** of the agent. * **Albiglutide** is a long-acting GLP-1 RA consisting of two GLP-1 molecules fused to **human albumin**. * Its large molecular size limits its penetration across the blood-brain barrier into the vomiting centers. * Clinical trials (e.g., HARMONY trials) demonstrated that Albiglutide has a significantly lower rate of nausea (approx. 10%) compared to other agents in its class. **Analysis of Incorrect Options:** * **Lixisenatide:** A short-acting agent. Short-acting GLP-1 RAs cause more pronounced inhibition of gastric emptying, leading to higher rates of acute nausea. * **Semaglutide & Liraglutide:** These are potent GLP-1 RAs. While highly effective for glycemic control and weight loss, they are associated with a higher incidence of GI distress (up to 20-40%), especially during the dose-escalation phase. **High-Yield Clinical Pearls for NEET-PG:** * **Weight Loss Potency:** Semaglutide > Liraglutide > Dulaglutide > Exenatide > Albiglutide. (Albiglutide is less effective for weight loss). * **Renal Safety:** Liraglutide is generally preferred in mild-to-moderate renal impairment; Exenatide must be avoided if CrCl <30 mL/min. * **Black Box Warning:** All GLP-1 RAs carry a risk of **Medullary Thyroid Carcinoma (MTC)** and are contraindicated in patients with Multiple Endocrine Neoplasia (MEN) type 2. * **Note:** Albiglutide was discontinued by the manufacturer (GSK) for commercial reasons, but it remains a high-yield "concept" question regarding side-effect profiles.

Question 428: Which of the following is the most potent glucocorticoid?

A. Hydrocortisone
B. Prednisolone
C. Betamethasone (Correct Answer)
D. Triamcinolone

Explanation: The potency of glucocorticoids is determined by their affinity for the glucocorticoid receptor and their duration of action. Glucocorticoids are generally classified into short, intermediate, and long-acting agents based on their anti-inflammatory potency relative to cortisol (hydrocortisone). **Why Betamethasone is correct:** Betamethasone and Dexamethasone are **long-acting glucocorticoids** with the highest anti-inflammatory potency. They are approximately **25–30 times more potent** than hydrocortisone. They also possess minimal to no mineralocorticoid (salt-retaining) activity, making them ideal for conditions where high-dose steroid therapy is required without causing fluid retention. **Analysis of Incorrect Options:** * **Hydrocortisone (A):** This is a short-acting steroid with a potency ratio of **1**. It is the pharmaceutical form of endogenous cortisol and possesses significant mineralocorticoid activity. * **Prednisolone (B):** This is an intermediate-acting steroid. It is approximately **4 times** more potent than hydrocortisone. * **Triamcinolone (D):** Also an intermediate-acting steroid, it is slightly more potent than prednisolone (about **5 times** more potent than hydrocortisone) but significantly less potent than betamethasone. **High-Yield NEET-PG Pearls:** 1. **Potency Hierarchy:** Betamethasone = Dexamethasone (25-30) > Triamcinolone (5) > Prednisolone (4) > Hydrocortisone (1). 2. **Fetal Lung Maturity:** Betamethasone is the preferred steroid to accelerate fetal lung maturity in preterm labor because it has better placental transfer and lower protein binding compared to other steroids. 3. **Mineralocorticoid Activity:** Long-acting steroids (Betamethasone/Dexamethasone) have **zero** mineralocorticoid activity, whereas Fludrocortisone has the highest. 4. **Topical Potency:** In topical formulations, Clobetasol propionate is considered one of the most potent (super-high potency) corticosteroids.

Question 429: Which among the following is a glucocorticoid synthesis inhibitor?

A. Mifepristone
B. Ketoconazole (Correct Answer)
C. Letrozole
D. Anastrozole

Explanation: **Explanation:** The correct answer is **Ketoconazole**. **1. Why Ketoconazole is correct:** Ketoconazole is an imidazole antifungal that [1], at high doses, acts as a potent **adrenocortical steroid synthesis inhibitor** [2]. It works by inhibiting several cytochrome P450 enzymes [1], most notably **11β-hydroxylase** and **17α-hydroxylase (CYP17)** [3]. By blocking these steps, it prevents the conversion of precursors into cortisol. It is clinically used in the medical management of **Cushing’s syndrome** to rapidly lower cortisol levels [2]. **2. Analysis of Incorrect Options:** * **Mifepristone (A):** This is a **glucocorticoid receptor antagonist** (and progesterone antagonist) [3]. It does not inhibit the *synthesis* of cortisol; instead, it blocks its action at the receptor level [3]. It is used for hyperglycemia in patients with endogenous Cushing’s syndrome. * **Letrozole (C) and Anastrozole (D):** These are **Aromatase inhibitors** (Third generation) [4]. They inhibit the conversion of androgens to estrogens and are primarily used in the treatment of hormone-receptor-positive breast cancer in postmenopausal women [4]. They have no significant effect on glucocorticoid synthesis. **3. High-Yield Clinical Pearls for NEET-PG:** * **Metyrapone:** Another synthesis inhibitor that selectively inhibits **11β-hydroxylase** [2]. It is the only adrenal inhibitor that can be used in **pregnancy**. * **Aminoglutethimide:** Inhibits the conversion of cholesterol to pregnenolone (the first step) [1]. * **Mitotane:** An adrenolytic drug used specifically for **adrenocortical carcinoma**. * **Side Effect Note:** Because Ketoconazole also inhibits androgen synthesis, it can cause **gynecomastia** and decreased libido in males.

Question 430: Which of the following drugs are used in the management of adrenal insufficiency?

A. Hydrocortisone
B. Adrenaline
C. Dexamethasone
D. Fludrocortisone (Correct Answer)

Explanation: **Explanation:** Adrenal insufficiency (Addison’s disease) is characterized by the inadequate production of both **glucocorticoids** (cortisol) and **mineralocorticoids** (aldosterone). Effective management requires replacing both components to maintain metabolic stability and electrolyte balance. **1. Why Fludrocortisone is the Correct Answer:** Fludrocortisone is a potent synthetic mineralocorticoid with significant salt-retaining activity. In primary adrenal insufficiency, the loss of aldosterone leads to hyponatremia, hyperkalemia, and hypotension. Fludrocortisone is the drug of choice to replace mineralocorticoid activity, ensuring sodium retention and potassium excretion. **2. Analysis of Incorrect Options:** * **Hydrocortisone (Option A):** While hydrocortisone is the mainstay for *glucocorticoid* replacement, it is often insufficient on its own for mineralocorticoid needs in primary adrenal insufficiency. (Note: In many MCQ formats, if only one must be chosen as the "specific" mineralocorticoid add-on, Fludrocortisone is the hallmark answer). * **Adrenaline (Option B):** Adrenaline is used for anaphylaxis and cardiac arrest. It is produced by the adrenal medulla, but its deficiency in adrenal insufficiency is clinically compensated by the sympathetic nervous system. * **Dexamethasone (Option C):** This is a pure, long-acting glucocorticoid with **zero** mineralocorticoid activity. While used in acute adrenal crises (as it doesn't interfere with cortisol assays), it is not ideal for long-term maintenance because it lacks salt-retaining properties. **High-Yield Clinical Pearls for NEET-PG:** * **Primary vs. Secondary:** Mineralocorticoid replacement (Fludrocortisone) is required in **Primary** Adrenal Insufficiency (Addison’s) but usually **not** in Secondary (Pituitary) insufficiency, as aldosterone is regulated by the RAAS, not ACTH. * **Crisis Management:** In an acute adrenal crisis, the priority is **IV Hydrocortisone** and aggressive fluid resuscitation (Normal Saline). * **Dosing:** Hydrocortisone is given in divided doses (2/3 in the morning, 1/3 in the evening) to mimic the natural circadian rhythm of cortisol.

Practice by Chapter

Hypothalamic and Pituitary Hormones

Practice Questions

Thyroid Drugs and Antithyroid Agents

Practice Questions

Insulin and Oral Hypoglycemic Agents

Practice Questions

Adrenocorticosteroids

Practice Questions

Sex Hormones: Estrogens and Progestins

Practice Questions

Androgens and Anabolic Steroids

Practice Questions

Hormonal Contraceptives

Practice Questions

Drugs Affecting Calcium Metabolism

Practice Questions

Drugs for Osteoporosis

Practice Questions

Pharmacological Management of Obesity

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free